ArticleBMC cancer2026
Clinical benefit of locoregional therapy for oligometastasis after surgery for pancreatic cancer: a single center retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of patients with pancreatic cancer (PC) is generally poor. However, favorable outcomes have recently been reported in selected patients with metastatic PC who receive multidisciplinary treatment. Oligometastasis (OM) represents a limited metastatic state and may be associated with better prognosis than multiple metastases (MM). The clinical role of locoregional therapy (LT) for postoperative OM remains unclear.
methodsWe included all consecutive patients with pancreatic malignancies who underwent macroscopically curative resection between 2013 and 2018. Patients with postoperative recurrence were divided into OM and MM groups. Survival outcomes and treatment after recurrence were compared between the groups.
resultsIn total, 150 patients were evaluated. Postoperative recurrence was classified as OM in 29 patients and MM in 71 patients. Among the patients with OM, 10 underwent LT. Overall survival and survival after recurrence were significantly longer in the OM group than in the MM group. Among patients with OM, those who underwent LT showed longer survival after recurrence than those who received chemotherapy alone.
conclusionsPatients with postoperative OM after pancreatic cancer surgery showed more favorable survival outcomes than those with MM. In carefully selected patients with postoperative OM, LT combined with chemotherapy was associated with longer survival after recurrence. However, because of the retrospective single-center design, small number of treated patients, and potential selection bias, LT should be regarded as a possible treatment option rather than an established therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.